Alnylam Pharmaceuticals Inc (ALNY)vsargenx NV ADR (ARGX)
ALNY
Alnylam Pharmaceuticals Inc
$312.17
+0.34%
HEALTHCARE · Cap: $42.29B
ARGX
argenx NV ADR
$663.93
-3.01%
HEALTHCARE · Cap: $43.52B
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 14% more annual revenue ($4.25B vs $3.71B). ARGX leads profitability with a 30.4% profit margin vs 8.4%. ARGX trades at a lower P/E of 36.0x. ARGX earns a higher WallStSmart Score of 63/100 (C+).
ALNY
Hold49
out of 100
Grade: D+
ARGX
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1934.6%
Fair Value
$15.84
Current Price
$312.17
$296.33 premium
Margin of Safety
-527.8%
Fair Value
$132.94
Current Price
$663.93
$530.99 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
Keeps 30 of every $100 in revenue as profit
Revenue surging 74.6% year-over-year
Every $100 of equity generates 20 in profit
Growing faster than its price suggests
Strong operational efficiency at 28.1%
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 52.4x book value
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 32.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Revenue Growth, Return on Equity. Profitability is solid with margins at 30.4% and operating margin at 28.1%. Revenue growth of 74.6% demonstrates continued momentum.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 136.9x leaves little room for execution misses.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
ALNY profiles as a hypergrowth stock while ARGX is a growth play — different risk/reward profiles.
ALNY carries more volatility with a beta of 0.38 — expect wider price swings.
ALNY is growing revenue faster at 84.9% — sustainability is the question.
ARGX generates stronger free cash flow (407M), providing more financial flexibility.
Bottom Line
ARGX scores higher overall (63/100 vs 49/100), backed by strong 30.4% margins and 74.6% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?